PMID- 35281594
OWN - NLM
STAT- MEDLINE
DCOM- 20220408
LR  - 20220408
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2022
DP  - 2022
TI  - Human Umbilical Cord Mesenchymal Stem Cells Prevent Bacterial Biofilm Formation.
PG  - 1530525
LID - 10.1155/2022/1530525 [doi]
LID - 1530525
AB  - Biofilm formation is easily found in patients suffered from ventilator-associated 
      pneumonia (VAP) in neonatal intensive care unit (NICU) and makes the VAP 
      infections not only harder to be treated but easier to relapse. In order to find 
      some novel ways to inhibit biofilm formation, this study describe a previously 
      unrecognized role for the human umbilical cord mesenchymal stem cells (hUCMSCs). 
      In addition to multiple differentiation, hUCMSCs have the ability to prevent the 
      biofilms formation in vitro by secreting antibacterial peptides (LL-37 and 
      hBD-2). This occurred while P. aeruginosa PA27853 and hUCMSCs were cocultured, 
      and the filtrated medium, which was the supernatant containing antibacterial 
      peptides (5.9 ng/ml of LL-37, 1.77 ng/ml of hBD-2), and inhibited the growth of 
      the bacterial biofilm on the surface of tracheal tube (2.5#, for preterm infant). 
      Using microarrays, we were able to demonstrate that the antibacterial peptides 
      from hUCMSC affected biofilm formation by downregulating the gene-encoded 
      polysaccharide biosynthesis protein. In addition, in order to find out the most 
      suitable concentration of hUCMSCs, P. aeruginosa was cocultured with eight-level 
      concentrations of hUCMSCs, and we found that the concentration of LL-37 was 
      positively correlated with the concentration of hUCMSCs. Meanwhile, the 
      concentration of LL-37 became stable while the hUCMSC concentration reaches 
      higher than 5 x 10(6) cells/ml. But the concentration of hBD-2 had no significant 
      correlation with hUCMSCs. The collection of these stem cells is not only limited 
      by ethics but also reduces host rejection. This makes it possible to use 
      autologous hUCMSCs to treat neonatal VAP.
CI  - Copyright (c) 2022 Haoming Yang et al.
FAU - Yang, Haoming
AU  - Yang H
AUID- ORCID: 0000-0001-6890-8064
AD  - Guangdong Women and Children Hospital, Guangzhou, China.
FAU - Xu, Fang
AU  - Xu F
AD  - Guangdong Women and Children Hospital, Guangzhou, China.
FAU - Zheng, Xuaner
AU  - Zheng X
AUID- ORCID: 0000-0003-0675-1561
AD  - Guangdong Women and Children Hospital, Guangzhou, China.
FAU - Yang, Shumei
AU  - Yang S
AUID- ORCID: 0000-0002-6015-1770
AD  - Guangdong Women and Children Hospital, Guangzhou, China.
FAU - Ren, Zhuxiao
AU  - Ren Z
AD  - Guangdong Women and Children Hospital, Guangzhou, China.
FAU - Yang, Jie
AU  - Yang J
AUID- ORCID: 0000-0002-7691-0241
AD  - Guangdong Women and Children Hospital, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20220303
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Anti-Bacterial Agents/metabolism
MH  - Biofilms
MH  - Humans
MH  - Infant, Newborn
MH  - Infant, Premature
MH  - *Mesenchymal Stem Cells/metabolism
MH  - *Umbilical Cord
PMC - PMC8913149
COIS- The authors report no conflict of interest.
EDAT- 2022/03/15 06:00
MHDA- 2022/04/09 06:00
PMCR- 2022/03/03
CRDT- 2022/03/14 05:24
PHST- 2021/04/09 00:00 [received]
PHST- 2022/02/02 00:00 [accepted]
PHST- 2022/03/14 05:24 [entrez]
PHST- 2022/03/15 06:00 [pubmed]
PHST- 2022/04/09 06:00 [medline]
PHST- 2022/03/03 00:00 [pmc-release]
AID - 10.1155/2022/1530525 [doi]
PST - epublish
SO  - Biomed Res Int. 2022 Mar 3;2022:1530525. doi: 10.1155/2022/1530525. eCollection 
      2022.